Search

for
Search:

Glossary Janus Kinase 3

enzyme involved in immune cell signaling pathways

Janus Kinase 3 (JAK3) is an enzyme that plays a crucial role in the signaling pathways of certain types of immune cells. It is involved in the transmission of signals from various cytokine receptors, which are important for the development and function of the immune system. Mutations or malfunctions in JAK3 can lead to immune disorders and have been targeted in treatments for conditions like alopecia areata and rheumatoid arthritis.

Related Terms

Research

5 / 1000+ results

research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata

23 citations , October 2024 in “British Journal of Dermatology”

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

research In‐silico Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its In‐vitro Evaluation

April 2020 in “The FASEB journal”

In in-vitro experiments, this study found that poncirin showed higher inhibitory activity against JAK3 than tofacitinib, suggesting potential for alopecia areata treatment.

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

63 citations , July 2024 in “Journal of the American Academy of Dermatology”

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index

research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index

September 2019 in “Journal of Investigative Dermatology”

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

research Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing

34 citations , June 2020 in “British journal of dermatology/British journal of dermatology, Supplement”

In this study, researchers observed that follicular damage and stem cell loss in frontal fibrosing alopecia may be mediated by immune attacks at the bulge region, suggesting potential for JAK/STAT-targeting treatments to prevent progression.

View more "janus kinase 3" in research →

Community Join

2 / 1000+ results

community What else is good. Besides the big 3.

in Chat 35 upvotes 1 year ago

Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

community Novel Formulation To Put An End To Hair Loss Once And For All.

in Research/Science 118 upvotes 10 months ago

A pharmacy student proposed a hair loss treatment using minoxidil, finasteride, clascoterone, and tretinoin, aiming for high effectiveness with minimal side effects. Reactions were mixed, with some questioning its feasibility and others showing interest.

View more "janus kinase 3" in community →

Learn

— no results

Try a deeper search in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →